WuXi PharmaTech’s toxicology facility in Suzhou has received a GLP certificate from the State Food and Drug Administration (SFDA) of the People’s Republic of China after successfully passing two inspections. Having assessed its processes and conditions under which studies are planned, performed, monitored, recorded, archived, and reported, the GLP certificate acknowledges the facility’s capacity to perform non-clinical lab studies under SFDA GLP regulations.   The inspection included an au...